Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Dalhus ML"'
Autor:
Trullas-Jimeno A; Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands., Delgado J; Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain. Electronic address: julio.delgado@ema.europa.eu., Garcia-Ochoa B; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain; Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands., Wang I; Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Statens Legemiddelverk, Oslo, Norway., Sancho-Lopez A; Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Payares-Herrera C; Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Dalhus ML; Statens Legemiddelverk, Oslo, Norway., Strøm BO; Statens Legemiddelverk, Oslo, Norway., Egeland EJ; Statens Legemiddelverk, Oslo, Norway., Enzmann H; Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Pignatti F; Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands.
Publikováno v:
ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100159. Date of Electronic Publication: 2021 May 20.
Autor:
Tzogani K; European Medicines Agency, Amsterdam, The Netherlands., Røshol H; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Olsen HH; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Aas IB; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Dalhus ML; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Håkonsen GD; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Nilssen LS; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Lindberg V; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Økvist M; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Bolstad B; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Statens legemiddelverk, Oslo, Norway., Rogovska I; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Zāļu valsts aǵentūra, Riga, Latvia., Karpova N; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Zāļu valsts aǵentūra, Riga, Latvia., Enzmann H; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Gisselbrecht C; Hospital Saint Louis, Paris, France., Pignatti F; European Medicines Agency, Amsterdam, The Netherlands.
Publikováno v:
The oncologist [Oncologist] 2020 Jul; Vol. 25 (7), pp. e1070-e1076. Date of Electronic Publication: 2020 Mar 10.